Core Viewpoint - Despite a slowdown in the sector in the second half of the year, there remains strong interest from capital, with nearly 8 billion yuan of net inflow over five consecutive trading days, indicating a new round of investment layout [1] Group 1: Global Trends - Over the past decade, the number of pharmaceutical transactions globally has shown a steady growth trend, with multinational corporations (MNCs) needing to replenish their pipelines due to profit pressures [1] - By 2030, products with sales exceeding 5 billion USD that are nearing patent expiration will total nearly 200 billion USD, driving MNCs' enthusiasm for business development (BD) [1] Group 2: Chinese Pharmaceutical Companies - Chinese pharmaceutical companies are increasingly competitive globally, with the total amount of license-out transactions exceeding 100 billion USD this year, doubling compared to 2024 [2] - From 2015 to 2024, the number of original innovative drugs entering clinical trials from Chinese companies reached 4,382, surpassing the 4,009 from the United States, with 704 new drugs entering clinical trials in 2024, ranking first globally [2] - The number of innovative drugs developed by Chinese companies that have entered late-stage clinical trials is comparable to that of the United States [2] Group 3: Technological Trends - Antibody-drug conjugates (ADC) have become a hot topic for license-out transactions among Chinese companies over the past three years, transitioning from a follower to a leader in innovation [2] - Chinese companies are rapidly following innovations in immuno-oncology (IO) and have the potential to surpass competitors, with some products already authorized for international markets [2] Group 4: Policy Environment - The average price reduction of drugs in the 2025 medical insurance negotiations is expected to stabilize, with a significant proportion of newly added drugs being domestically produced [3] - Future centralized procurement may focus more on comprehensive value assessments rather than solely on low prices, emphasizing efficacy, quality, and patient accessibility [3] Group 5: Investment Opportunities - Focus on IO and ADC as foundational therapies for tumors, particularly with the upcoming expiration of PD-1 patents, which may lead to a market shift towards second-generation IO therapies [3] - Highlighted companies in the IO and ADC sectors include: 3SBio, Innovent Biologics, CanSino Biologics, Rongchang Biopharmaceuticals, Huahai Pharmaceutical, Yiming Pharmaceutical, Lepu Medical, Kelun-Biotech, and CSPC Pharmaceutical [3][5] - Emphasis on the internationalization of Chinese pharmaceutical companies, with a long-term view of the industry evolving into global leaders, particularly in innovative drugs and medical devices [3] - Notable companies in the medical device sector include Mindray Medical, United Imaging Healthcare, BGI Genomics, and Haitai New Light [3][5] - The CXO industry is expected to improve due to better supply-demand dynamics, with global investment recovery likely to boost client demand [4] - Key CXO leaders to watch include WuXi AppTec, WuXi Biologics, Kelun Pharmaceutical, Tigermed, and Jiuzhou Pharmaceutical [4][5]

11月20日，由德国因戈尔施塔特市、商务部投资促进事务局、中华人民共和国驻慕尼黑总领事馆共同主 办，巴伐利亚中国中心、中国国际投资促进中心（德国）承办的第十一届巴伐利亚中国日在因戈尔施塔 特成功举行。本届活动聚焦中德生命健康产业合作，吸引了来自政府、科研和企业界的百余名代表参 会。 因戈尔施塔特市市长迈克尔·科恩表示，因市与中国长期保持良好合作，在制造业与科研领域基础坚 实。当前因市正推进产业转型，生命健康产业成为重点方向，与中国发展优势高度契合。他欢迎更多中 国企业与机构参与因市创新生态，共同拓展新的合作机遇。 商务部投资促进事务局局长刘民强指出，中德经贸合作对全球产业链稳定意义重大，两国领导人已为未 来合作指明方向。中国经济持续释放高质量发展和开放红利，生命健康、生物医药和人工智能正成为合 作新亮点。投资促进局将继续为双方企业提供专业服务，推动更多项目落地。 德国巴伐利亚州经济部总司长王猛博士强调，中国是巴州第一大贸易伙伴，双方在制造业和生命科学领 域优势互补。巴州具备领先的科研体系和生命健康创新生态，始终欢迎中国企业投资发展。他表示，愿 推动双方在科研、产业与人才交流等方面进一步深化合作。 中国驻慕尼黑 ...

Core Viewpoint - Zhejiang Huahai Pharmaceutical Co., Ltd. announced the release of part of the share pledge by its major shareholder, Zhou Minghua, which may indicate a positive outlook on the company's financial health and shareholder confidence [2][3]. Group 1: Shareholder Information - As of the announcement date, Zhou Minghua holds a total of 224,418,890 shares, representing 14.99% of the company's total share capital [2]. - After the release of the pledge, Zhou Minghua has 57,500,000 shares under pledge, which accounts for 25.62% of his total holdings and 3.84% of the company's total share capital [2]. Group 2: Pledge Release Details - Recently, Zhou Minghua notified the company that 6,480,000 shares pledged to Shanghai Pudong Development Bank have been released from pledge [3]. - The company will fulfill its information disclosure obligations if there are any future pledge plans by Zhou Minghua [3].

Group 1: Core Insights - The current wave of innovative drugs is driven by China's participation in new technologies, with advancements in ADC, bispecific antibodies, second-generation IO, and GLP-1 [1] - The global pharmaceutical transaction volume has steadily increased, with total transaction amounts rising from $56.9 billion to $187.4 billion over the past decade, while China's transaction amounts surged from $3.1 billion to $57.1 billion [1] - By 2024, China's transaction volume is expected to account for approximately 30% of global pharmaceutical transactions [1] Group 2: Sector Analysis - In oncology, the combination of IO and ADC therapies remains strong, with significant transactions in the PD-1 bispecific antibody space; the sales of Pembrolizumab are projected to reach $29.482 billion in 2024 [2] - The autoimmune disease sector is witnessing a shift as older drugs face patent expirations, with new opportunities emerging in Th2 and Th17 pathways; Dupilumab is expected to lead with $14.1 billion in sales in 2024 [2] - The cardiovascular and metabolic disease market continues to grow, with GLP-1 receptor agonists projected to exceed $50 billion in global sales in 2024 [3] Group 3: Future Technologies - New technologies such as next-generation ADCs, TCE therapies, universal/in vivo CART technologies, gene therapy, and small nucleic acid technologies are anticipated to lead future disease treatments [4]

关于股东部分股份解除质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 | 证券代码：600521 | 证券简称：华海药业 | 公告编号：临 | 2025-120 号 | | --- | --- | --- | --- | | 债券代码：110076 | 债券简称：华海转债 | | | 浙江华海药业股份有限公司 二、股份质押情况 截至本公告披露日，周明华先生累计质押股份情况如下： 重要内容提示: 截至本公告披露日，浙江华海药业股份有限公司（以下简称"公司"） 5%以上股东周明华先生持有公司股份总数为 224,418,890 股，占公司总股本的比 例为 14.99%。本次股份解除质押后，周明华先生处于质押状态的股份累计数为 57,500,000 股，占其所持有公司股份总数的 25.62%，占公司总股本的比例为 3.84%。 一、本次股份解除质押情况 近日，公司接到股东周明华先生的通知，其质押给上海浦东发展银行股份有 限公司张江科技支行的公司股份 648 万股已办理了解除质押手续，具体情况如 下: 单位：股 | 股东 ...

Group 1 - On November 24, Huahai Pharmaceutical executed a block trade of 1 million shares, with a transaction value of 16.52 million yuan, accounting for 5.47% of the total trading volume for the day [1][2] - The transaction price was 16.52 yuan, which represents a discount of 2.99% compared to the market closing price of 17.03 yuan [1][2]

Core Insights - The pharmaceutical MNC supply chain has extremely high entry barriers, requiring years for supplier certification through cross-departmental audits in technology, quality, EHS, and compliance. Once included in the qualified supplier list, a strong lock-in effect is formed, making it difficult for new entrants to disrupt the existing supply structure even if they meet technical standards, thus demonstrating a strong first-mover advantage [4][7]. - MNCs demand far more than conventional quality compliance, emphasizing full-process controllability and risk management capabilities. Compliance with guidelines such as EU GMP and ICHQ is required, along with the establishment of traceability systems and safety stock. Any process changes or relocation of production sites must undergo strict and time-consuming certification [4][7]. - In procurement decisions, MNCs are relatively insensitive to price factors, prioritizing the integrity of the supply chain over cost. For MNCs, API costs represent only a small portion of their terminal formulation sales, leading them to pay a premium for stable, traceable, and zero major quality incident supply capabilities, viewing supply chain resilience as a core competitive advantage rather than a cost item. Thus, entering the MNC supply chain often means effectively avoiding "price internalization" [4][7]. - Investment recommendations include innovative drug and device companies such as Furuya Co., Aonlikang, Shutaishen, Weichuang Bio, and others. From the perspective of CXO and raw materials, companies like WuXi AppTec, Jiuzhou Pharmaceutical, Chengda Pharmaceutical, and others are suggested for attention [4][7]. Market Performance Overview - As of November 21, 2025, the TTM-PE of the pharmaceutical and biotechnology industry is 48.84 times, which is 100% higher than the historical lowest PE valuation of 24.38 times on January 3, 2019. The premium rate relative to the CSI 300 is 252%, exceeding the historical lowest valuation premium of 124% on February 6, 2018, by 128 percentage points, and is 11 percentage points higher than the average valuation premium rate of 241% over the past decade [8][12]. - From November 17 to November 21, 2025, the pharmaceutical and biotechnology sector experienced a decline of 6.88%, ranking 22nd among 27 sub-industries. The chemical raw materials sector saw the largest decline at -8.60% [12][15]. Industry Dynamics - Pfizer's Class 1 new drug, Matacizumab, was approved for marketing on November 21, 2025, for the routine prevention and treatment of bleeding in patients with severe hemophilia A or B [20]. - Boehringer Ingelheim's Class 1 new drug, BI764198, was proposed for inclusion as a breakthrough therapy on November 18, 2025, targeting primary focal segmental glomerulosclerosis [21]. - The PD-1 inhibitor H drug, Surulutumab, developed by Fuhong Hanlin, was officially included as a breakthrough therapy on November 20, 2025, for gastric cancer treatment [22]. - On November 17, 2025, FDA approved the biosimilar of Tysabri, developed by Sandoz, for multiple sclerosis and Crohn's disease [23].

Core Viewpoint - The domestic R&D demand is showing marginal improvement, driven by the overseas expansion of innovative drugs, leading to a recovery in R&D orders and stabilization of industry prices after a decline in 2023. The CRO sector is expected to see better performance growth by 2026, while the CDMO industry has also reached a bottom and is poised for continued strong growth due to robust demand for new molecules and new orders [1][2][3]. CRO Sector - The domestic R&D demand is recovering, with an increase in orders and stabilization of prices, indicating a clear upward trend for CRO companies. Clinical CROs like Tigermed, Nossan, and Prasis are expected to see revenue growth turning positive by 2025, with significant contributions from overseas business [2][3]. - The recognition of domestic CRO clinical data is improving, which is beneficial for companies like Tigermed [2]. CDMO Sector - The CDMO sector has seen a recovery in performance, with new orders continuing to improve quarterly. The global demand for innovative drug R&D is driving growth in new orders and backlog [3]. - The industry is benefiting from increased capacity utilization and profitability, with a strong certainty of performance and profit growth expected to continue into 2026 [3]. Life Sciences Sector - The life sciences upstream sector is experiencing a dual drive from domestic substitution and overseas expansion, with urgent demand for domestic alternatives in areas like cell culture media and biological reagents. Companies are expected to capture market share through new product categories and cost-effective offerings [4]. - The demand for specific segments such as drug efficacy, antibodies, and proteins is increasing, indicating a clear long-term growth logic for the industry [4]. API Sector - The raw material pharmaceutical industry is currently in a phase of price bottoming and supply surplus, with traditional product performance under pressure. However, companies are extending their business into generics, innovative drugs, and specialty APIs, which may lead to value reconstruction through business structure optimization [5]. - The valuation of raw material pharmaceutical companies is at a low point, presenting opportunities based on changes in new business layouts [5]. Investment Recommendations - For clinical and preclinical CROs, companies like Tigermed, Nossan, and Yinos are recommended due to the gradual recovery of the industry and expected improvement in order structure [6]. - In the CDMO sector, companies such as WuXi AppTec, WuXi Biologics, and others with strong fundamentals and capacity advantages are highlighted for their potential benefits from industry recovery and high demand for new molecules [6]. - In the life sciences upstream sector, companies like Baitai Biotechnology and others are recommended due to accelerated domestic substitution and strong overseas growth [6]. - Companies like Pro Pharma and Huahai Pharmaceutical are noted for their new business layouts that are expected to contribute significant value increments [6].

Core Viewpoint - Zhejiang Huahai Pharmaceutical Co., Ltd. announced that its subsidiary, Shanghai Huatai Biopharmaceutical Co., Ltd., has successfully completed a key clinical trial for HB0017 injection, aimed at treating moderate to severe plaque psoriasis, achieving all primary and key secondary efficacy endpoints [1][2]. Drug Information - Drug Name: HB0017 Injection - Formulation: Injection - Indication: Psoriasis - Registration Category: Class 1 therapeutic biological product [1]. Clinical Trial Details - The Phase III clinical trial included 408 patients with moderate to severe plaque psoriasis in China, demonstrating significant efficacy with a PASI 75 response rate and sPGA 0/1 response rate at week 12 [1]. - The treatment regimen is expected to offer the longest dosing interval among similar products, with efficacy indicators continuing to improve and stabilize during the maintenance phase [1]. - HB0017 shows strong competitive advantages over existing products targeting the same pathway, both in the core treatment phase (first 12 weeks) and the maintenance phase (12-52 weeks) [1]. - Safety profile of HB0017 is favorable, with no new safety signals identified compared to previous studies and similar drugs [1]. Investment and Development Costs - The company has invested approximately RMB 37.205 million in the development of the HB0017 injection project to date [3]. Future Development - In addition to the completed Phase III trial for plaque psoriasis, HB0017 is also undergoing a Phase III trial for ankylosing spondylitis, with positive results from previous Phase II trials [2].

Core Points - Huahai Pharmaceutical announced that its subsidiary, Shanghai Huatai Biopharmaceutical Co., Ltd., and its wholly-owned subsidiary, Huabo Biopharmaceutical Technology (Shanghai) Co., Ltd., have successfully completed a key clinical trial for HB0017 injection for the treatment of psoriasis, achieving all primary and key secondary efficacy endpoints [2] Group 1 - The clinical trial was a multicenter, double-blind, randomized, placebo-controlled study [2] - The trial results indicate significant efficacy of HB0017 in treating psoriasis [2] - This development may enhance Huahai Pharmaceutical's position in the biopharmaceutical market [2]